Daxor (DXR) Stock Price, News & Analysis

Company Overview

Daxor Corporation (NASDAQ: DXR) is a medical device and biotechnology company focused on blood-volume measurement and related diagnostic applications. Its primary product is the BVA-100 Blood Volume Analyzer, a system designed to measure a patient’s total blood volume, plasma volume, red blood cell volume and hematocrit.

The BVA-100 uses a blood sample and an iodine-131-labeled albumin tracer to provide quantitative blood-volume measurements. The technology is intended to support clinical assessment and management in areas including heart failure, critical care, kidney disease, blood disorders and perioperative care, where accurate information about a patient’s fluid and blood-volume status can assist treatment decisions.

Daxor markets its technology primarily to hospitals and other healthcare providers and also supports clinical research involving blood-volume measurement. The company is headquartered in New York and has been publicly traded under the symbol DXR for several decades. Michael Feldschuh has served as the company’s chief executive officer.

Key Stats

• Today's Range: $8.36 to $8.59
• 50-Day Range: $8.45 to $11.72
• 52-Week Range: $8.24 to $14.76
• Volume: 9,162 shs
• Average Volume: 11,623 shs
• Market Capitalization: $49.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Daxor Stock Analysis - MarketRank™

Daxor scored higher than 44% of companies evaluated by MarketBeat, and ranked 631st out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Daxor has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Daxor has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the float of Daxor has been sold short.

Short Interest Ratio / Days to Cover

Daxor has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daxor has recently decreased by 69.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Daxor does not currently pay a dividend.

Dividend Growth

Daxor does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.39

News Sentiment

Daxor has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Daxor this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Daxor insiders have not sold or bought any company stock.

Percentage Held by Insiders

51.50% of the stock of Daxor is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

1.34% of the stock of Daxor is held by institutions.

Company Calendar

• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:DXR
• Previous Symbol: NYSEAMERICAN:DXR
• CIK: 27367
• Web: www.daxor.com
• Phone: 212-244-0555
• Fax: 212-244-0806
• Employees: 37
• Year Founded: 1970

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 5,840,000
• Free Float: 2,831,000
• Market Cap: $49.65 million
• Optionable: Not Optionable
• Beta: 0.43